As demand for new cellular research innovations continues to soar worldwide, Rainbow Biosciences, the biotechnology division of Rainbow Coral Corp., is increasing its investment in the marketing and development of a breakthrough 3D bioprinting technology.
The company announced today that it is in final negotiations to further its involvement in Nano 3D Biosciences (n3D), a cutting-edge technology company drawing international interest with its revolutionary BiO Assay, the first commercially available 3D bioprinting system designed for high throughput and high-content drug screening.
RBCC took an equity interest in n3D in 2012, not long after the companies formed a joint venture to market and develop new technologies for the fast-growing, global biotechnology marketplace. Now, the company plans to double down on that investment position as n3D becomes a leading stakeholder in an industry forecast to be worth $10 billion by 2030.
“We’re proud of our partnership with n3D, and we look forward to helping deliver the amazing potential of the BiO Assay to researchers all over the world,” said RBCC CEO Kimberly Palmer.
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.